Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 20/20 | 0.74 |
| ▸ | CTSL | P07711 | 19/20 | 0.74 |
| ▸ | CTSS | P25774 | 18/20 | 0.74 |
| ▸ | CTSV | O60911 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6214635 | 0.89 | CTSK (0.73) | CTSKCTSLCTSSCTSVCTSB | |
| SCHEMBL7015060 | 0.87 | CTSK (0.57) | CTSKCTSLCTSSCTSVCTSB | |
| SCHEMBL6842065 | 0.86 | CTSK (0.56) | CTSKCTSLCTSSCTSVCTSB | |
| SCHEMBL7097499 | 0.86 | CTSK (0.76) | CTSKCTSLCTSSCTSVCTSB | |
| SCHEMBL6841469 | 0.85 | CTSK (1.00) | CTSKCTSLCTSSCTSVCTSB | |
| SCHEMBL6215911 | 0.83 | CTSK (0.81) | CTSKCTSLCTSSCTSVCTSB | |
| SCHEMBL4318828 | 0.82 | CTSK (0.70) | CTSKCTSLCTSSCTSVCTSB | |
| SCHEMBL6744240 | 0.82 | CTSK (0.70) | CTSKCTSLCTSSCTSVCTSB | |
| SCHEMBL6263458 | 0.82 | CTSK (0.72) | CTSKCTSLCTSSCTSVCTSB | |
| SCHEMBL5983414 | 0.81 | CTSK (0.70) | CTSKCTSLCTSSCTSVCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
| EP-1278502-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1278502-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001089451-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885CTSL 11/4885CTSS 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.